miRagen Therapeutics, Inc. (MGEN) Q1 2019 Results Earnings Conference Call May 8, 2019 4:30 PM ET Company Participants Dan Ferry - LifeSci Advisors Bill Marshall - President and Chief Executive Officer Jason Leverone - Chief Financial Officer Paul Rubin - Executive Vice President of Research and Development Adam Levy - Chief Business Officer Conference Call Participants Jonathan Miller - Evercore ISI Liana Moussatos - Wedbush Securities Eun Yang - Jefferies Madhu Kumar - Robert W. Baird George Zavoico - B. ...

(Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2019 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q For the transition period from to Commission File No. 001-36483 MIRAGEN THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware (State or other ...

Restoring Biological Harmony for Patients with Debilitating Disease Pg. 1 miRagen Therapeutics NASDAQ: MGEN Oppenheimer 29th Annual Healthcare Conference March 20, 2019 Cautionary Note Regarding Forward-Looking Statements Pg. 2 This presentation contains forward-looking statements relating to Miragen Therapeutics, Inc., including statements about our plans to obtain funding, develop and commercialize our therapeutic candidates, our planned clinical trials, the timing of and our ability to obtain and maintai ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION FORM 10-K ____________________________________________ Washington, D.C. 20549 ____________________________________________ (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2018 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-36483 _____________________________________ ...

miRagen Therapeutics, Inc. (MGEN) Q4 2018 Earnings Conference Call March 13, 2019 4:30 PM ET Company Participants Daniel Ferry - LifeSci Advisors, LLC William Marshall - Co-Founder, President and Chief Executive Officer Jason Leverone - Chief Financial Officer Paul Rubin - Executive Vice President of Research and Development Adam Levy - Chief Business Officer Conference Call Participants Jonathan Miller - Evercore ISI Suji Jeong - Jefferies LLC Vasiliana Moussatos - Wedbush Securities Inc. Madhu Kumar - Rob ...